Lancet Diab & Endo:大庆糖尿病预防研究23年随访结果公布

2014-04-04 佚名 中国医学论坛报

4月3日,北京中日友好医院李光伟教授等在《柳叶刀·糖尿病与内分泌学》(The Lancet Diabetes & Endocrinology)杂志发表了“大庆糖尿病预防研究”23年随访结果:中国糖耐量受损人群进行生活方式干预6年,随访23年显示心血管病死亡和全因死亡显著降低。这是全球首项证明生活方式干预可降低糖尿病高危人群心血管病死亡和全因死亡的高质量随机对照试验。 1986年,

4月3日,北京中日友好医院李光伟教授等在《柳叶刀·糖尿病与内分泌学》(The Lancet Diabetes & Endocrinology)杂志发表了“大庆糖尿病预防研究”23年随访结果:中国糖耐量受损人群进行生活方式干预6年,随访23年显示心血管病死亡和全因死亡显著降低。这是全球首项证明生活方式干预可降低糖尿病高危人群心血管病死亡和全因死亡的高质量随机对照试验。

1986年,李教授等将糖耐量受损患者随机分为生活方式干预组(n=438)和对照组(n=138),干预组给予生活方式干预6年。随访23年显示,心血管病导致的累计死亡率在生活方式干预组为11.9%,在对照组为19.6%;全因死亡率在生活方式干预组为28.1%,在对照组为38.4%。

英国剑桥大学韦勒姆教授在同期述评中将上述结果描述为“一个真正的突破”。

详细阅读:Lancet Diab & Endo:对糖耐量受损者(IGT)进行生活方式干预显示出长期获益

原始出处:

Guangwei Li, Ping Zhang, Jinping Wang, Yali An, Qiuhong Gong, Edward W Gregg, Wenying Yang, Bo Zhang, Ying Shuai, Jing Hong, Michael M Engelgau, Hui Li, Gojka Roglic, Yinghua Hu, Peter H Bennett.Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study . In Press, Corrected Proof, Available online 3 April 2014

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (17)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2045466, encodeId=d35a20454661f, content=<a href='/topic/show?id=a982e680663' target=_blank style='color:#2F92EE;'>#糖尿病预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76806, encryptionId=a982e680663, topicName=糖尿病预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Fri Sep 12 09:48:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004352, encodeId=be0e200435248, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78621, encryptionId=54ebe8621cf, topicName=结果公布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Wed Jul 02 08:48:00 CST 2014, time=2014-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827763, encodeId=92c2182e76389, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Nov 30 23:48:00 CST 2014, time=2014-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818757, encodeId=f4f11818e57c8, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jul 23 03:48:00 CST 2014, time=2014-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8989, encodeId=bae98989d9, content=李教授一直兢兢业业、一丝不苟的做学问,是晚辈们学习的楷模, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ybf, createdTime=Mon Apr 14 21:39:00 CST 2014, time=2014-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8963, encodeId=8a1e89637a, content=中国原创,造福世界, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zhangyusheng, createdTime=Sun Apr 13 09:36:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8911, encodeId=46e489119d, content=鼓舞人心!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=904a69384, createdName=liguojuan@2011, createdTime=Wed Apr 09 23:16:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8884, encodeId=e24e888485, content=能不能给个链接?, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=207.106.176.170, createdTime=Tue Apr 08 08:19:00 CST 2014, time=2014-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8876, encodeId=edbd88e6e7, content=挺有意思的内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=112.53.64.218, createdTime=Mon Apr 07 17:11:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8861, encodeId=d68c886196, content=这个研究在东北大庆这个地方进行的,所以命名为大庆研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.231.255.56, createdTime=Mon Apr 07 09:27:00 CST 2014, time=2014-04-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2045466, encodeId=d35a20454661f, content=<a href='/topic/show?id=a982e680663' target=_blank style='color:#2F92EE;'>#糖尿病预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76806, encryptionId=a982e680663, topicName=糖尿病预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Fri Sep 12 09:48:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004352, encodeId=be0e200435248, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78621, encryptionId=54ebe8621cf, topicName=结果公布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Wed Jul 02 08:48:00 CST 2014, time=2014-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827763, encodeId=92c2182e76389, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Nov 30 23:48:00 CST 2014, time=2014-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818757, encodeId=f4f11818e57c8, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jul 23 03:48:00 CST 2014, time=2014-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8989, encodeId=bae98989d9, content=李教授一直兢兢业业、一丝不苟的做学问,是晚辈们学习的楷模, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ybf, createdTime=Mon Apr 14 21:39:00 CST 2014, time=2014-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8963, encodeId=8a1e89637a, content=中国原创,造福世界, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zhangyusheng, createdTime=Sun Apr 13 09:36:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8911, encodeId=46e489119d, content=鼓舞人心!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=904a69384, createdName=liguojuan@2011, createdTime=Wed Apr 09 23:16:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8884, encodeId=e24e888485, content=能不能给个链接?, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=207.106.176.170, createdTime=Tue Apr 08 08:19:00 CST 2014, time=2014-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8876, encodeId=edbd88e6e7, content=挺有意思的内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=112.53.64.218, createdTime=Mon Apr 07 17:11:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8861, encodeId=d68c886196, content=这个研究在东北大庆这个地方进行的,所以命名为大庆研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.231.255.56, createdTime=Mon Apr 07 09:27:00 CST 2014, time=2014-04-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2045466, encodeId=d35a20454661f, content=<a href='/topic/show?id=a982e680663' target=_blank style='color:#2F92EE;'>#糖尿病预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76806, encryptionId=a982e680663, topicName=糖尿病预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Fri Sep 12 09:48:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004352, encodeId=be0e200435248, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78621, encryptionId=54ebe8621cf, topicName=结果公布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Wed Jul 02 08:48:00 CST 2014, time=2014-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827763, encodeId=92c2182e76389, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Nov 30 23:48:00 CST 2014, time=2014-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818757, encodeId=f4f11818e57c8, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jul 23 03:48:00 CST 2014, time=2014-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8989, encodeId=bae98989d9, content=李教授一直兢兢业业、一丝不苟的做学问,是晚辈们学习的楷模, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ybf, createdTime=Mon Apr 14 21:39:00 CST 2014, time=2014-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8963, encodeId=8a1e89637a, content=中国原创,造福世界, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zhangyusheng, createdTime=Sun Apr 13 09:36:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8911, encodeId=46e489119d, content=鼓舞人心!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=904a69384, createdName=liguojuan@2011, createdTime=Wed Apr 09 23:16:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8884, encodeId=e24e888485, content=能不能给个链接?, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=207.106.176.170, createdTime=Tue Apr 08 08:19:00 CST 2014, time=2014-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8876, encodeId=edbd88e6e7, content=挺有意思的内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=112.53.64.218, createdTime=Mon Apr 07 17:11:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8861, encodeId=d68c886196, content=这个研究在东北大庆这个地方进行的,所以命名为大庆研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.231.255.56, createdTime=Mon Apr 07 09:27:00 CST 2014, time=2014-04-07, status=1, ipAttribution=)]
    2014-11-30 howi
  4. [GetPortalCommentsPageByObjectIdResponse(id=2045466, encodeId=d35a20454661f, content=<a href='/topic/show?id=a982e680663' target=_blank style='color:#2F92EE;'>#糖尿病预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76806, encryptionId=a982e680663, topicName=糖尿病预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Fri Sep 12 09:48:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004352, encodeId=be0e200435248, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78621, encryptionId=54ebe8621cf, topicName=结果公布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Wed Jul 02 08:48:00 CST 2014, time=2014-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827763, encodeId=92c2182e76389, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Nov 30 23:48:00 CST 2014, time=2014-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818757, encodeId=f4f11818e57c8, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jul 23 03:48:00 CST 2014, time=2014-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8989, encodeId=bae98989d9, content=李教授一直兢兢业业、一丝不苟的做学问,是晚辈们学习的楷模, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ybf, createdTime=Mon Apr 14 21:39:00 CST 2014, time=2014-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8963, encodeId=8a1e89637a, content=中国原创,造福世界, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zhangyusheng, createdTime=Sun Apr 13 09:36:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8911, encodeId=46e489119d, content=鼓舞人心!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=904a69384, createdName=liguojuan@2011, createdTime=Wed Apr 09 23:16:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8884, encodeId=e24e888485, content=能不能给个链接?, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=207.106.176.170, createdTime=Tue Apr 08 08:19:00 CST 2014, time=2014-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8876, encodeId=edbd88e6e7, content=挺有意思的内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=112.53.64.218, createdTime=Mon Apr 07 17:11:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8861, encodeId=d68c886196, content=这个研究在东北大庆这个地方进行的,所以命名为大庆研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.231.255.56, createdTime=Mon Apr 07 09:27:00 CST 2014, time=2014-04-07, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2045466, encodeId=d35a20454661f, content=<a href='/topic/show?id=a982e680663' target=_blank style='color:#2F92EE;'>#糖尿病预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76806, encryptionId=a982e680663, topicName=糖尿病预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Fri Sep 12 09:48:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004352, encodeId=be0e200435248, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78621, encryptionId=54ebe8621cf, topicName=结果公布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Wed Jul 02 08:48:00 CST 2014, time=2014-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827763, encodeId=92c2182e76389, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Nov 30 23:48:00 CST 2014, time=2014-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818757, encodeId=f4f11818e57c8, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jul 23 03:48:00 CST 2014, time=2014-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8989, encodeId=bae98989d9, content=李教授一直兢兢业业、一丝不苟的做学问,是晚辈们学习的楷模, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ybf, createdTime=Mon Apr 14 21:39:00 CST 2014, time=2014-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8963, encodeId=8a1e89637a, content=中国原创,造福世界, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zhangyusheng, createdTime=Sun Apr 13 09:36:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8911, encodeId=46e489119d, content=鼓舞人心!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=904a69384, createdName=liguojuan@2011, createdTime=Wed Apr 09 23:16:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8884, encodeId=e24e888485, content=能不能给个链接?, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=207.106.176.170, createdTime=Tue Apr 08 08:19:00 CST 2014, time=2014-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8876, encodeId=edbd88e6e7, content=挺有意思的内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=112.53.64.218, createdTime=Mon Apr 07 17:11:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8861, encodeId=d68c886196, content=这个研究在东北大庆这个地方进行的,所以命名为大庆研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.231.255.56, createdTime=Mon Apr 07 09:27:00 CST 2014, time=2014-04-07, status=1, ipAttribution=)]
    2014-04-14 ybf

    李教授一直兢兢业业、一丝不苟的做学问,是晚辈们学习的楷模

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2045466, encodeId=d35a20454661f, content=<a href='/topic/show?id=a982e680663' target=_blank style='color:#2F92EE;'>#糖尿病预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76806, encryptionId=a982e680663, topicName=糖尿病预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Fri Sep 12 09:48:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004352, encodeId=be0e200435248, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78621, encryptionId=54ebe8621cf, topicName=结果公布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Wed Jul 02 08:48:00 CST 2014, time=2014-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827763, encodeId=92c2182e76389, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Nov 30 23:48:00 CST 2014, time=2014-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818757, encodeId=f4f11818e57c8, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jul 23 03:48:00 CST 2014, time=2014-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8989, encodeId=bae98989d9, content=李教授一直兢兢业业、一丝不苟的做学问,是晚辈们学习的楷模, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ybf, createdTime=Mon Apr 14 21:39:00 CST 2014, time=2014-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8963, encodeId=8a1e89637a, content=中国原创,造福世界, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zhangyusheng, createdTime=Sun Apr 13 09:36:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8911, encodeId=46e489119d, content=鼓舞人心!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=904a69384, createdName=liguojuan@2011, createdTime=Wed Apr 09 23:16:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8884, encodeId=e24e888485, content=能不能给个链接?, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=207.106.176.170, createdTime=Tue Apr 08 08:19:00 CST 2014, time=2014-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8876, encodeId=edbd88e6e7, content=挺有意思的内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=112.53.64.218, createdTime=Mon Apr 07 17:11:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8861, encodeId=d68c886196, content=这个研究在东北大庆这个地方进行的,所以命名为大庆研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.231.255.56, createdTime=Mon Apr 07 09:27:00 CST 2014, time=2014-04-07, status=1, ipAttribution=)]
    2014-04-13 zhangyusheng

    中国原创,造福世界

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2045466, encodeId=d35a20454661f, content=<a href='/topic/show?id=a982e680663' target=_blank style='color:#2F92EE;'>#糖尿病预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76806, encryptionId=a982e680663, topicName=糖尿病预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Fri Sep 12 09:48:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004352, encodeId=be0e200435248, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78621, encryptionId=54ebe8621cf, topicName=结果公布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Wed Jul 02 08:48:00 CST 2014, time=2014-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827763, encodeId=92c2182e76389, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Nov 30 23:48:00 CST 2014, time=2014-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818757, encodeId=f4f11818e57c8, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jul 23 03:48:00 CST 2014, time=2014-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8989, encodeId=bae98989d9, content=李教授一直兢兢业业、一丝不苟的做学问,是晚辈们学习的楷模, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ybf, createdTime=Mon Apr 14 21:39:00 CST 2014, time=2014-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8963, encodeId=8a1e89637a, content=中国原创,造福世界, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zhangyusheng, createdTime=Sun Apr 13 09:36:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8911, encodeId=46e489119d, content=鼓舞人心!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=904a69384, createdName=liguojuan@2011, createdTime=Wed Apr 09 23:16:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8884, encodeId=e24e888485, content=能不能给个链接?, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=207.106.176.170, createdTime=Tue Apr 08 08:19:00 CST 2014, time=2014-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8876, encodeId=edbd88e6e7, content=挺有意思的内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=112.53.64.218, createdTime=Mon Apr 07 17:11:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8861, encodeId=d68c886196, content=这个研究在东北大庆这个地方进行的,所以命名为大庆研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.231.255.56, createdTime=Mon Apr 07 09:27:00 CST 2014, time=2014-04-07, status=1, ipAttribution=)]
    2014-04-09 liguojuan@2011

    鼓舞人心!

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2045466, encodeId=d35a20454661f, content=<a href='/topic/show?id=a982e680663' target=_blank style='color:#2F92EE;'>#糖尿病预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76806, encryptionId=a982e680663, topicName=糖尿病预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Fri Sep 12 09:48:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004352, encodeId=be0e200435248, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78621, encryptionId=54ebe8621cf, topicName=结果公布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Wed Jul 02 08:48:00 CST 2014, time=2014-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827763, encodeId=92c2182e76389, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Nov 30 23:48:00 CST 2014, time=2014-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818757, encodeId=f4f11818e57c8, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jul 23 03:48:00 CST 2014, time=2014-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8989, encodeId=bae98989d9, content=李教授一直兢兢业业、一丝不苟的做学问,是晚辈们学习的楷模, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ybf, createdTime=Mon Apr 14 21:39:00 CST 2014, time=2014-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8963, encodeId=8a1e89637a, content=中国原创,造福世界, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zhangyusheng, createdTime=Sun Apr 13 09:36:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8911, encodeId=46e489119d, content=鼓舞人心!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=904a69384, createdName=liguojuan@2011, createdTime=Wed Apr 09 23:16:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8884, encodeId=e24e888485, content=能不能给个链接?, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=207.106.176.170, createdTime=Tue Apr 08 08:19:00 CST 2014, time=2014-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8876, encodeId=edbd88e6e7, content=挺有意思的内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=112.53.64.218, createdTime=Mon Apr 07 17:11:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8861, encodeId=d68c886196, content=这个研究在东北大庆这个地方进行的,所以命名为大庆研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.231.255.56, createdTime=Mon Apr 07 09:27:00 CST 2014, time=2014-04-07, status=1, ipAttribution=)]
    2014-04-08 207.106.176.170

    能不能给个链接?

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2045466, encodeId=d35a20454661f, content=<a href='/topic/show?id=a982e680663' target=_blank style='color:#2F92EE;'>#糖尿病预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76806, encryptionId=a982e680663, topicName=糖尿病预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Fri Sep 12 09:48:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004352, encodeId=be0e200435248, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78621, encryptionId=54ebe8621cf, topicName=结果公布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Wed Jul 02 08:48:00 CST 2014, time=2014-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827763, encodeId=92c2182e76389, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Nov 30 23:48:00 CST 2014, time=2014-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818757, encodeId=f4f11818e57c8, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jul 23 03:48:00 CST 2014, time=2014-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8989, encodeId=bae98989d9, content=李教授一直兢兢业业、一丝不苟的做学问,是晚辈们学习的楷模, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ybf, createdTime=Mon Apr 14 21:39:00 CST 2014, time=2014-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8963, encodeId=8a1e89637a, content=中国原创,造福世界, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zhangyusheng, createdTime=Sun Apr 13 09:36:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8911, encodeId=46e489119d, content=鼓舞人心!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=904a69384, createdName=liguojuan@2011, createdTime=Wed Apr 09 23:16:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8884, encodeId=e24e888485, content=能不能给个链接?, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=207.106.176.170, createdTime=Tue Apr 08 08:19:00 CST 2014, time=2014-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8876, encodeId=edbd88e6e7, content=挺有意思的内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=112.53.64.218, createdTime=Mon Apr 07 17:11:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8861, encodeId=d68c886196, content=这个研究在东北大庆这个地方进行的,所以命名为大庆研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.231.255.56, createdTime=Mon Apr 07 09:27:00 CST 2014, time=2014-04-07, status=1, ipAttribution=)]
    2014-04-07 112.53.64.218

    挺有意思的内容

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2045466, encodeId=d35a20454661f, content=<a href='/topic/show?id=a982e680663' target=_blank style='color:#2F92EE;'>#糖尿病预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76806, encryptionId=a982e680663, topicName=糖尿病预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Fri Sep 12 09:48:00 CST 2014, time=2014-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004352, encodeId=be0e200435248, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78621, encryptionId=54ebe8621cf, topicName=结果公布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Wed Jul 02 08:48:00 CST 2014, time=2014-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827763, encodeId=92c2182e76389, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Nov 30 23:48:00 CST 2014, time=2014-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818757, encodeId=f4f11818e57c8, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jul 23 03:48:00 CST 2014, time=2014-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8989, encodeId=bae98989d9, content=李教授一直兢兢业业、一丝不苟的做学问,是晚辈们学习的楷模, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ybf, createdTime=Mon Apr 14 21:39:00 CST 2014, time=2014-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8963, encodeId=8a1e89637a, content=中国原创,造福世界, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zhangyusheng, createdTime=Sun Apr 13 09:36:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8911, encodeId=46e489119d, content=鼓舞人心!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=904a69384, createdName=liguojuan@2011, createdTime=Wed Apr 09 23:16:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8884, encodeId=e24e888485, content=能不能给个链接?, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=207.106.176.170, createdTime=Tue Apr 08 08:19:00 CST 2014, time=2014-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8876, encodeId=edbd88e6e7, content=挺有意思的内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=112.53.64.218, createdTime=Mon Apr 07 17:11:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8861, encodeId=d68c886196, content=这个研究在东北大庆这个地方进行的,所以命名为大庆研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.231.255.56, createdTime=Mon Apr 07 09:27:00 CST 2014, time=2014-04-07, status=1, ipAttribution=)]
    2014-04-07 116.231.255.56

    这个研究在东北大庆这个地方进行的,所以命名为大庆研究

    0

相关资讯

Nature:研究发现二甲双胍抗癌的直接证据

近年来,一类被称作为双胍类的抗糖尿病药物证实与某些抗癌特性有关联。一些回顾性研究表明,广泛应用的糖尿病药物二甲双胍可以使某些癌症患者受益。尽管存在这一有趣的关联,人们一直以来却并不清楚二甲双胍是如何发挥它的抗癌效应的,更重要的是它会在哪些患者中发挥这一效应。 现在,来自麻省理工怀特黑德研究所(Whitehead, MIT)的科学家们开始解开这一谜团,确定了一条使得癌细胞能够在低葡萄糖环境中存活的

PNAS:日本科学家开发出糖尿病治疗疫苗

糖尿病患者为了降低血糖值,需要持续服用药物。 日前,日本科学家在PNAS上报告称,他们新开发的治疗疫苗可成功降低血糖值,且效果能够持续两三个月,省去了需要经常服药的麻烦。 人们进食后,小肠释放的激素胰高血糖素样肽-1(GLP-1)会促进胰腺分泌胰岛素,从而降低血糖值。但是,血液中微量存在的二肽基肽酶-4(DPP-4)则会分解 GLP-1,从而导致血糖升高。开发阻碍 DPP-4 发挥作用的抑制剂

JCEM:天芪降糖胶囊减慢糖尿病患者糖耐量减退

最近一项多中心临床试验表明,中药复方天芪降糖胶囊可能具有抑制糖耐量异常的作用。在这项研究中,共420例糖耐量受损(impaired glucose tolerance,IGT)患者被随机分为天芪降糖胶囊组和安慰剂组,共治疗12个月。每3个月进行口服糖耐量测试,同时,所有患者均受到相同的生活方式教育。主要终点为最终IGT转换为II型糖尿病的比例。研究发现,在整个12个月试验中,天芪降糖胶囊湘鄂赣18

纪立农:糖尿病相关卒中风险的性别差异

2014年3月7日纪立农教授在The Lancet 上发布了一则评论,就女性糖尿病患者的糖尿病相关卒中风险显著高于男性患者进行了讨论。 在普通人群中,卒中在男性中比在女性中更为常见。而且,男性的年龄特异性卒中发生率也高于女性,但年龄35~44岁和大于85岁的女性应除外,在这两个年龄段中,女性的年龄特异性卒中发病率略高于男性。妊娠和口服避孕药的使用等因素可能是导致女性35~44岁期间卒中风险增

Lancet:女性糖尿病患者卒中风险高于男性

糖尿病是世界范围内致死和致残的主要病因,同时也是卒中的一项主要危险因素。不同性别的人群中间糖尿病引起的卒中风险是否有差异,以及有何种差异尚不清楚。 为此,来自澳大利亚布里斯班昆士兰大学的Huxley 教授及其团队进行了一项系统性回顾和荟萃分析,评估与男性相比,糖尿病对女性卒中风险的相对影响,该研究结果在线发表在2014年03月07日的The Lancet杂志上。 该研究中,Huxle

JAAOS:糖尿病骨骼肌肉表现和骨科围手术期处置

糖尿病是未经控制的高血糖状态。尽管目前对糖尿病的病理生理有了足够的了解,并且已经开发出了控制血糖较有针对性的药物,但该病的发生率及由该病引发的严重后果后遗症的人群仍在持续上升。糖尿病导致的神经,血管,免疫系统等并发损伤使得这类患者的骨骼肌肉结果较正常更易受损。 糖尿病患者的足部损伤是目前为止最为常见的骨科损伤类型,除此之外,上肢,脊柱,肌肉等也均较正常患者更易出现问题。骨科医生目前面